Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment
نویسندگان
چکیده
Gonadotropin-releasing hormone analogues are common treatment option in central precocious puberty in childhood as well as in endometriosis, infertility, and prostate cancer in adults. Pseudotumor cerebri is a rare side effect observed in adults. We present the case of a girl with precocious puberty treated with triptorelin acetate who developed pseudotumor cerebri after the 4th dose. She had headaches, and her blood pressure was detected to be above the 99 percentile. There were no causes underlying of hypertension such as cardiac, renal, or endocrine. Neurological examination was normal except bilateral papilledema. Cranial magnetic resonance imaging was normal. Cerebrospinal fluid (CSF) opening pressure was elevated. Triptorelin therapy was ceased and acetazolamide was applied; CSF pressure returned to normal. We observed pseudotumor cerebri after precocious puberty treatment, a finding for the first time ever seen in childhood.
منابع مشابه
Resurgence of Minimal Stimulation In Vitro Fertilization with A Protocol Consisting of Gonadotropin Releasing Hormone-Agonist Trigger and Vitrified-Thawed Embryo Transfer
Minimal stimulation in vitro fertilization (mini-IVF) consists of a gentle controlled ovarian stimulation that aims to produce a maximum of five to six oocytes. There is a misbelief that mini-IVF severely compromises pregnancy and live birth rates. An appraisal of the literature pertaining to studies on mini-IVF protocols was performed. The advantages of minimal stimulation protocols are report...
متن کاملA Comparison of Outcomes from IVF Cycles Stimulated with either Recombinant Luteinizing Hormone or Human Menopausal Gonadotropins in Subjects Treated with Long Gonadotropin Releasing Hormone Agonist Protocols, a Retrospective Analysis.
Objective The objective of this study is to compare rates of pregnancy and IVF parameters in subjects who were stimulated with follicle stimulating hormone (FSH) plus either recombinant human luteinizing hormone (r-LH) or human menopausal gonadotropins (hMG), in long gonadotropin releasing hormone (GnRH) agonist IVF protocols. MaterialsAndMethods This is a cohort study of patients undergoing IV...
متن کاملComparison of pregnancy outcomes of frozen embryo transfers in women undergoing artificial endometrial preparation with and without short and long-acting gonadotropin releasing hormone agonists
Background & aim: There are conflicting results regarding the benefit of gonadotropin releasing hormone (GnRH) agonist treatment on frozen embryo transfer (FET) outcome. No study was found to compare pregnancy outcome between patients undergoing short and long acting types of GnRH agonist for FET cycles. This study aimed to assess the effectiveness of short and long ac...
متن کاملThe effect of administration of gonadotropin releasing hormone analogue at estrus or during luteal phase on reproductive performance of dairy cows maintained under sub-temperate climate
Overall, 531 dairy cows were inseminated with the aim to study their reproductive performance following administration of GnRH analogue on different days of estrous cycle with different doses. These cows were divided into six treatment and one control group. Depending upon different treatment groups, Buserelin acetate was injected at a dose of 10.5 µg or 21.0 µg on different days (0, 5 or 12) o...
متن کاملتاثیر درمان با آنالوگهای طولانیاثر گنادوتروپین بر اندکس توده بدنی در دختران دچار بلوغ زودرس
Background: Gonadotropin-releasing hormone analog (GnRHa) therapy is used in central precocious puberty (CPP) worldwide and it is the treatment of choice for this condition. Many of the previous studies concerning the effect of gonadotropin-releasing hormone analog (GnRHa) therapy on height. Much less attention has been paid to changes in body weight. However, concerns have been expressed that ...
متن کامل